HLA-DRα (h4): 293T Lysate: sc-159470



The Power to Question

BACKGROUND

Major histocompatibility complex (MHC) class II molecules destined for presentation to CD4+ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in MHC II- α/β dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane-anchored heavy chain and a light chain (β-2-Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles.

REFERENCES

- Horejsi, V. et al. 1986. Characterization of seven new monoclonal antibodies against human DR, DR + DP and DQ1 + DQ3 antigens. Tissue Antigens 28: 288-297.
- 2. Horejsi, V. et al. 1986. Monoclonal antibodies against human leucocyte antigens. I. Antibodies against β -2-Microglobulin, immunoglobulin κ light chains, HLA-DR-like antigens, T8 antigen, T1 antigen, a monocyte antigen, and a pan-leucocyte antigen. Folia Biol. 32: 12-25.
- 3. Kropshofer, H., et al. 1998. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J. 17: 2971-2981.
- 4. Siegmund, T., et al. 1999. HLA-DMA and HLA-DMB alleles in German patients with type 1 diabetes mellitus. Tissue Antigens 54: 291-294.
- Arndt, S.O., et al. 2000. Functional HLA-DM on the surface of B cells and immature dendritic cells. EMBO J. 19: 1241-1251.
- 6. Brunet, A., et al. 2000. Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-D0 β . J. Biol. Chem. 275: 37062-37071.
- 7. Doebele, C.R., et al. 2000. Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity 13: 517-527.
- 8. Louis-Plence, P., et al. 2000. The down-regulation of HLA-DM gene expression in rheumatoid arthritis is not related to their promoter polymorphism. J. Immunol. 165: 4861-4869.
- Toussirot, E., et al. 2000. The association of HLA-DM genes with rheumatoid arthritis in Eastern France. Hum. Immunol. 61: 303-308.

CHROMOSOMAL LOCATION

Genetic locus: HLA-DRA (human) mapping to 6p21.32

PRODUCT

HLA-DR α (h4): 293T Lysate represents a lysate of human HLA-DR α transfected 293T cells and is provided as 100 μ g protein in 200 μ l SDS-PAGE buffer.

APPLICATIONS

HLA-DR α (h4): 293T Lysate is suitable as a Western Blotting positive control for human reactive HLA-DR α antibodies. Recommended use: 10-20 μ l per lane


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.


HLA-DR α (B-10): sc-55592 is recommended as a positive control antibody for Western Blot analysis of enhanced human HLA-DR α expression in HLA-DR α transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA







HLA-DR α (G-7): sc-55593. Western blot analysis of HLA-DR α expression in non-transfected: sc-117752 (**A**) and human HLA-DR α transfected: sc-159470 (**B**) 293T whole cell Ivsates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com